Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Roivant Sciences (ROIV – Research Report). The company’s ...

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) has earned a consensus rating of “Buy” from the seven brokerages that are presently covering the stock, MarketBeat.com reports.

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Bank of New York Mellon Corp raised its stake in Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) by 17.4% during the fourth quarter, according to the company in its most recent 13F filing with the ...

Explore Roivant Sciences stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ROIV. Tech Stocks Surge, Steelmakers Jump On Trump's 25% Tariffs, Copper Hits 9 ...

In its fourth quarter 2024 investor letter, Tourlite Capital Management emphasized stocks such as Roivant Sciences Ltd. (NASDAQ:ROIV). Roivant Sciences Ltd. (NASDAQ:ROIV) is a commercial-stage ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the ...

In this article, we are going to take a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) stands against the other cash-rich mid cap stocks. Cash flow is the money moving in and out of a business ...